药物治疗策略,以促进自我免疫中调节性T细胞功能
Robert C Wright1, Daniel J Campbell2, Megan K Levings3
1Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.
Current opinion in immunology
|April 5, 2025
概括
用药物促进调节性T细胞 (Tregs) 是治疗自身免疫性疾病的一个有希望的策略. 这些疗法旨在恢复免疫耐受性,减少对广泛免疫抑制的依赖.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 自身免疫性疾病研究研究
背景情况:
- 自身免疫性疾病发生在免疫系统错误地攻击身体自身组织时,因为自身耐受性丧失.
- 调节性T细胞 (Tregs) 对于抑制自身反应和维持免疫平衡至关重要.
- 目前的治疗方法往往涉及广泛的免疫抑制,强调了针对性治疗的必要性.
研究的目的:
- 审查最近在药理学策略上的进展,以增强体内调节性T细胞 (Treg) 功能.
- 通过调节Tregs来探索重新定位和新型药物疗法的潜力,以治疗自身免疫性疾病.
- 讨论Treg增强疗法在1型糖尿病和移植等疾病中的应用.
主要方法:
- 对Treg增强药理学方法的当前文献的综述.
- 讨论特定的药物类别,包括介素-2衍生物,TNF受体2激动剂和氨酸激酶2抑制剂.
- 分析共刺激阻塞和淋巴切除疗法在优化Treg功能中的作用.
主要成果:
- 药理干预可以提高Treg数和/或体内功能.
- 介素-2,TNF受体2激动剂和TK2抑制剂显示Treg调节的潜力.
- 协同刺激阻塞和淋巴细胞消耗剂可能会预先确定基于Treg的疗法的免疫环境.
结论:
- 在体内优化Tregs的药物治疗策略对于诱导自身免疫性疾病的持久缓解具有显著的前景.
- 向Tregs为广泛的免疫抑制提供了潜在的替代方案,从而导致更具体,更有效的治疗方法.
- 对Treg促进药物的进一步研究可能会彻底改变对1型糖尿病等自身免疫疾病的治疗.
相关概念视频
T Cell Types and Functions
724
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
724
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
119
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
119
Cell-mediated Immune Responses
66.5K
Overview
66.5K
Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
Inflammatory Response
1.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.7K


